Tom McCourt
CEO
Replay available
Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2024 Earnings Call
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) Q3 2024 earnings conference call, held 2024-11-07. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Shravan Imani
CFO
Mohit Bansal
Biotech and Pharma Analyst, Wells Fargo
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Ironwood Pharmaceuticals, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:03.636 Great. Thank you very much for joining us today. 00:00:03.636 -- 00:00:08.362 My name is Mohit Bansal. I'm one of the biotech and pharma analysts here at Wells Fargo, 00:00:08.362 -- 00:00:12.227 and I'm joined by Tim Ironwood today. So we have Tom McCourt, the CEO of the company, 00:00:12.227 -- 00:00:15.211 and we have Shravan Imani, the CFO of the company. 00:00:15.211 -- 00:00:16.292 Thank you very much for joining us. 00:00:16.292 -- 00:00:17.674 Great to be here. 00:00:17.674 -- 00:00:22.841 Great. So maybe let's just start with those who are new to the story. 00:00:22.841 -- 00:00:25.905 They are trying to learn the story. 00:00:25.905 -- 00:00:29.109 Talk a little bit about the company, just a brief overview of the company and what you're 00:00:29.109 -- 00:00:29.590 up to. 00:00:29.590 -- 00:00:35.376 Sure. So Ironwood is a GI-focused healthcare company. 00:00:35.376 -- 00:00:40.943 Our primary focus is in GI medicines. And about five years ago, 00:00:40.943 -- 00:00:46.249 we reorganized the company to really strengthen our overall skills and capabilities 00:00:46.249 -- 00:00:50.173 around GI disease, both with regard to development and commercial. 00:00:50.173 -- 00:00:55.400 We have a lead asset in Linzess, which is the market-leading brand 00:00:55.400 -- 00:00:57.722 for the treatment of IBS and chronic constipation. 00:00:57.722 -- 00:01:02.723 It continues to thrive in the market. It's really been a remarkable drug and 00:01:02.723 -- 00:01:06.167 story in that, you know, in year 12, 00:01:06.167 -- 00:01:11.493 based on, you know, based on really a platform of about 4.5 million prescriptions, 00:01:11.493 -- 00:01:16.559 it's still growing at about 10% a year, which is really remarkably steady 00:01:16.559 -- 00:0...